Health Care & Life Sciences » Biotechnology | Charles River Laboratories International Inc.

Charles River Laboratories International Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
105,416.00
129,924.00
152,037.00
156,086.00
125,586.00
227,218
Depreciation, Depletion & Amortization
96,636.00
96,445.00
94,881.00
126,658.00
131,159.00
161,779
Other Funds
594.00
5,360.00
7,476.00
8,234.00
4,858.00
47,031
Funds from Operations
234,402.00
255,906.00
278,617.00
330,393.00
312,131.00
426,326
Changes in Working Capital
25,357.00
3,774.00
9,617.00
30,018.00
5,943.00
14,814
Net Operating Cash Flow
209,045.00
252,132.00
288,234.00
300,375.00
318,074.00
441,140
Capital Expenditures
39,154.00
56,925.00
63,252.00
55,288.00
82,431.00
Sale of Fixed Assets & Businesses
-
-
-
-
72,462.00
Purchase/Sale of Investments
5,982.00
5,648.00
7,163.00
13,706.00
37,089.00
Net Investing Cash Flow
75,953.00
299,071.00
322,163.00
688,426.00
74,395.00
Issuance/Reduction of Debt, Net
11,500.00
104,384.00
75,183.00
388,030.00
135,579.00
Net Financing Cash Flow
84,237.00
61,414.00
4,548.00
390,726.00
208,476.00
Net Change in Cash
46,242.00
4,096.00
42,076.00
321.00
46,437.00
Free Cash Flow
169,891.00
195,207.00
224,982.00
245,087.00
235,643.00
Deferred Taxes & Investment Tax Credit
846.00
7,060.00
2,689.00
1,945.00
28,254.00
9,702
Net Assets from Acquisitions
29,218.00
234,267.00
247,651.00
648,482.00
25,012.00
Other Sources
307.00
-
-
3,694.00
-
Change in Capital Stock
72,143.00
48,330.00
78,111.00
10,930.00
68,039.00
Exchange Rate Effect
2,613.00
10,379.00
12,695.00
2,996.00
11,234.00
Other Uses
1,906.00
2,231.00
4,097.00
2,056.00
2,325.00

About Charles River Laboratories International

View Profile
Address
251 Ballardvale Street
Wilmington Massachusetts 01887
United States
Employees -
Website http://www.criver.com
Updated 07/08/2019
Charles River Laboratories International, Inc. is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions. It operates through the following business segments: Research Models & Services, Discovery & Safety Assessment, and Manufacturing Support. The Research Models & Services segment comprises of the production and sale of research models, and also offers services designed to support its client's use of research models in screening non-clinical drug candidates.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.